November 21, 2014
The FDA has approved an extended release hydrocodone bitartrate, an opioid analgesic to treat severe chronic pain.
Hydrocodone bitartrate (Hysingla ER, Purdue Pharma) has some properties that may deter abuse because it is difficult to break, crush or dissolve and becomes a viscous gel that is difficult to inject when dissolved. Abuse and overdose, however, still are possible. It is intended only for pain that requires daily, 24-hour, long-term treatment and is not intended to be taken as needed.